CVS Health says Larry Merlo, the company's current president and CEO, will retire in the spring, and an Aetna executive will take his place, in today's bite-sized hospital and health industry news from Maryland, Rhode Island, and Washington, D.C.
Maryland: An FDA advisory panel in an 8-1 vote on Friday declined to recommend that the agency approve Biogen's Alzheimer's drug candidate aducanumab, citing a lack of evidence showing that the experimental treatment slows the disease's progression. The panel said data from Biogen's late-stage clinical trial did not provide "strong evidence" showing aducanumab effectively treats Alzheimer's. The advisory panel's decision was surprising, as the panel disagreed with FDA reviewers' positive assessment of Biogen's data supporting the drug candidate's approval. The panel's recommendation is nonbinding, meaning FDA does not have to follow the suggestion (Lovelace, CNBC, 11/6; Belluck, New York Times, 11/6; Marchione/Perrone, Associated Press, 11/6).
Create your free account to access 1 resource, including the latest research and webinars.
You have 1 free members-only resource remaining this month.
1 free members-only resources remaining
1 free members-only resources remaining
Never miss out on the latest innovative health care content tailored to you.